PTC Therapeutics Inc. (NASDAQ:PTCT)’s share price fell 1.1% during mid-day trading on Tuesday . The company traded as low as $8.15 and last traded at $8.21, with a volume of 186,710 shares trading hands. The stock had previously closed at $8.30.

A number of brokerages have recently issued reports on PTCT. JPMorgan Chase & Co. cut their price target on shares of PTC Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, August 5th. Citigroup Inc. increased their price target on shares of PTC Therapeutics from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Monday, August 8th. Cowen and Company reiterated a “hold” rating on shares of PTC Therapeutics in a report on Sunday, August 7th. Zacks Investment Research upgraded shares of PTC Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 12th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of PTC Therapeutics in a report on Friday, May 6th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company’s stock. PTC Therapeutics currently has an average rating of “Hold” and an average price target of $34.72.

The company’s market cap is $282.55 million. The stock has a 50 day moving average of $7.19 and a 200-day moving average of $8.55.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.27) by $0.13. During the same quarter in the previous year, the firm posted ($1.14) EPS. The company had revenue of $15.40 million for the quarter, compared to analyst estimates of $15.24 million. PTC Therapeutics’s quarterly revenue was up 150.0% on a year-over-year basis. Equities analysts anticipate that PTC Therapeutics Inc. will post ($4.95) EPS for the current fiscal year.

Other institutional investors have modified their holdings of the company. BlackRock Advisors LLC increased its position in shares of PTC Therapeutics by 2.3% in the fourth quarter. BlackRock Advisors LLC now owns 505,966 shares of the biopharmaceutical company’s stock worth $16,393,000 after buying an additional 11,568 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of PTC Therapeutics by 49.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,872,220 shares of the biopharmaceutical company’s stock worth $60,660,000 after buying an additional 621,079 shares in the last quarter. Jennison Associates LLC increased its position in shares of PTC Therapeutics by 5.9% in the fourth quarter. Jennison Associates LLC now owns 1,023,987 shares of the biopharmaceutical company’s stock worth $33,177,000 after buying an additional 57,092 shares in the last quarter. Marshall Wace LLP increased its position in shares of PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock worth $1,439,000 after buying an additional 14,926 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 2,485 shares in the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.